May 06, 2026 07:14 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Jolt to TMC! Supreme Court rejects plea challenging central staff deployment at Bengal counting centres | Bangladesh MP warns of refugee crisis if BJP wins West Bengal polls | Diplomatic row: Bangladesh summons Indian envoy over Himanta Biswa Sarma remarks | Supreme Court grants Pawan Khera anticipatory bail in case over allegations against Himanta Biswa Sarma's wife | ‘Not necessary to humiliate me with arrest’: Pawan Khera to SC over remarks on Himanta Biswa Sarma’s wife | ‘Let’s not choose for people capable of choosing’: Supreme Court to Centre on teen pregnancy termination | I-PAC co-founder Vinesh Chandel gets bail after Bengal polls conclude | Exit Polls Give Bengal to BJP—But One Survey Begs to Differ | Big defence push: Rajnath Singh to hold high-stakes talks with Italy’s Defence Minister | “Voting without fear”: PM Modi hails record turnout in West Bengal polls
Covid-19 vaccines

Two Covid-19 vaccine candidates await DCGI approval for emergency use in India

| @indiablooms | Jan 03, 2021, at 04:24 pm

New Delhi/IBNS: Two Covid-19 vaccine candidates in India-Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield-now awaits the approval of the Drugs Controller General of India (DCGI) for emergency use after they have been cleared by the government-appointed panel.

DCGI chief Dr Venugopal G Somani is expected to share details about the vaccine candidates on Sunday.

The government-appointed panel of experts on Saturday cleared the emergency use of indigenous COVID-19 vaccine Covaxin manufactured by Hyderabad-based Bharat Biotech and recommended for approval to the regulator Drugs Controller General of India (DCGI).

The recommendation for the home-grown vaccine came a day after the expert panel cleared Covishield developed by Oxford University and pharma major AstraZeneca to be manufactured by Serum Institute of India (SII).

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) recommended the Drugs Controller General of India (DCGI) to grant permission to Bharat Biotech's Covaxin.

According to reports, the SEC met on Jan 1 and 2 and made the recommendations for the consideration and final decision of DGCI, said the Union Health Ministry.

The Serum Institute of India (SII) is making the vaccine Covishield developed by Oxford University and pharma major AstraZeneca, while Bharat Biotech has partnered with the Indian Council of Medical Research (ICMR) for its indigenous Covaxin.

The final decision to recommend Bharat Biotech's Covaxin came after it presented updated data and justification and request for consideration of their proposal amid cases of mutant Coronavirus strain.

The committee noted that the vaccine has the potential to target mutated coronavirus strains, media reports said.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.